In Hepatitis, One Transformation May Soon Be Followed By Next
SAN FRANCISCO – Hepatitis C treatment is in a strange space right now. The approval earlier this year of the first two direct-acting antiviral drugs, Incivek (telaprevir, Vertex Pharmaceuticals Inc.) and Victrelis (boceprevir, Merck & Co. Inc.) has brought new options to hepatitis C patients.
The approval of telaprevir and boceprevir has already prompted the American Association for the Study of Liver Diseases to release new treatment guidelines for hepatitis C.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST